These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 15632378)

  • 21. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
    Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
    Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
    Mürdter TE; Schroth W; Bacchus-Gerybadze L; Winter S; Heinkele G; Simon W; Fasching PA; Fehm T; ; Eichelbaum M; Schwab M; Brauch H
    Clin Pharmacol Ther; 2011 May; 89(5):708-17. PubMed ID: 21451508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.
    Wu AH; Lorizio W; Tchu S; Lynch K; Gerona R; Ji W; Ruan W; Ruddy KJ; Desantis SD; Burstein HJ; Ziv E
    Breast Cancer Res Treat; 2012 Jun; 133(2):677-83. PubMed ID: 22294487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
    J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
    Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
    Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
    Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
    Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
    Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
    J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Lien EA; Ueland PM; Lønning PE
    J Natl Cancer Inst; 2004 Jun; 96(11):884; author reply 884-5. PubMed ID: 15173277
    [No Abstract]   [Full Text] [Related]  

  • 33. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coprescription of tamoxifen and medications that inhibit CYP2D6.
    Sideras K; Ingle JN; Ames MM; Loprinzi CL; Mrazek DP; Black JL; Weinshilboum RM; Hawse JR; Spelsberg TC; Goetz MP
    J Clin Oncol; 2010 Jun; 28(16):2768-76. PubMed ID: 20439629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
    Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
    J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
    MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
    Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
    Gjerde J; Geisler J; Lundgren S; Ekse D; Varhaug JE; Mellgren G; Steen VM; Lien EA
    BMC Cancer; 2010 Jun; 10():313. PubMed ID: 20565970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
    Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
    BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
    Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
    Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.